Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.46 |
| ▸ | EGFR known ✓ | P00533 | 3/20 | 0.39 |
| ▸ | CDK6 known ✓ | Q00534 | 1/20 | 0.37 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 0.36 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.36 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.36 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.36 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.36 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.36 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.36 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.36 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.36 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.36 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.36 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.36 |
| ▸ | ITK known ✓ | Q08881 | 1/20 | 0.36 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.36 |
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 0.36 |
| ▸ | NTRK2 known ✓ | Q16620 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31308615 | 1.00 | AXL (0.47) | AXLNUDT1PIK3CAPIK3CDPIK3CB | |
| Hydrochloric Acid SCHEMBL311520 | 1.00 | AXL (0.47) | AXLNUDT1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL29407705 | 0.98 | — | — | |
| SCHEMBL2078432 | 0.98 | AXL (0.48) | AXLNUDT1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL64925 | 0.98 | — | — | |
| SCHEMBL7500296 | 0.96 | AXL (0.47) | AXLNUDT1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL3845938 | 0.96 | AXL (0.47) | AXLNUDT1PIK3CAPIK3CDPIK3CB | |
| SCHEMBL15880172 | 0.90 | AXL (0.42) | AXLNUDT1PIK3CAPIK3CDPIK3CB | |
| Methylene Chloride SCHEMBL27892265 | 0.90 | AXL (0.42) | AXLNUDT1PIK3CAPIK3CDPIK3CB | |
| Urea SCHEMBL15380856 | 0.88 | RIPK1 (0.49) | AXLNUDT1PIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360157-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4370504-A1 | PROCESS AND INTERMEDIATES FOR PREPARING BARICITINIB | Incyte Corporation (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4200300-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | Incyte Corporation (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-4200278-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | Incyte Corporation (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023288197-A1 | PROCESS AND INTERMEDIATES FOR PREPARING BARICITINIB | INCYTE CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022040180-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR | INCYTE CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040172-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A JAK1 INHIBITOR | INCYTE CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| CN-106661031-B | Pyrrolopyrimidine compounds or its salt, pharmaceutical composition and application containing it | 大鹏药品工业株式会社 | 2019-07-23 | — | — | CN | disclosed |
| CN-108997351-A | Containing substitution to chloro acetyl piperazine compounds and the preparation method and application thereof | 山东大学 | 2018-12-14 | — | — | CN | disclosed |
| CN-106661031-A | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | 大鹏药品工业株式会社 | 2017-05-10 | — | — | CN | disclosed |
| CN-104470926-A | Substituted pyrrolopyrimidines | Bayer Pharma AG | 2015-03-25 | — | — | CN | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| CN-1289501-C | Fused heterotricyclic compound, process for preparing compounds and drugs containing the same | EISAI CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| CN-1409713-A | Tricyclic fused heterocyclic compound, process for producing the same, and pharmaceutical comprising the same | EISAI CO LTD (JP) | 2003-04-09 | — | — | CN | disclosed |
| CN-1037513-C | Pyrimidine compound and preparation method of medicinal salt thereof | MITSUI PETROCHEMICAL IND (JP) | 1998-02-25 | — | — | CN | disclosed |
| CN-1090846-A | The preparation method of pyrimidines and its pharmaceutical salts | MITSUI PETROCHEMICAL IND (JP) | 1994-08-17 | — | — | CN | disclosed |
| CN-1045390-A | Pyrimidine compound and preparation method and pharmaceutical use of pharmaceutical salt thereof | MITSUI PETROCHEMICAL IND (JP) | 1990-09-19 | — | — | CN | disclosed |
| EP-0305184-A1 | Pyrimidines or their pharmaceutically acceptable salts thereof | MITSUI PHARMACEUTICALS, INC. (JP) | 1989-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360157-A1 | TYK2 INHIBITORS | TYK2, JAK2, ABL1 | PIK3CA 582/4885PIK3CD 535/4885EGFR 366/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | PIK3CA 178/4885PIK3CD 280/4885EGFR 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.